COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746031
Recruitment Status : Completed
First Posted : September 3, 2008
Last Update Posted : October 25, 2010
NHS Lothian
Information provided by:
University of Edinburgh

Brief Summary:

Fibroids are present in up to 80% of women of reproductive age. Associated heavy menstrual bleeding is often an indication for surgery. At present there are no long-term medical treatments for fibroids. There is an unmet need for a pharmacologic agent able to reduce excessive bleeding and other symptoms associated with increased uterine volume, which could prevent or significantly delay surgery without causing significant unwanted hypoestrogenic side effects and allow preservation of fertility.

The purpose of this study is to investigate and validate novel MR imaging as a non-invasive biomarker for monitoring responses to medical interventions aimed at reduction of excessive menstrual bleeding and decrease in uterine/ fibroid volume. MR imaging is non-invasive, does not involve ionizing radiation and new techniques have the potential to resolve tissue detail to near cellular level.

The investigators are aiming to establish the feasibility and reproducibility of novel MR imaging techniques in the evaluation of treatment response in women with fibroids and to provide mechanistic information on whether the reduction in blood flow of uterine/fibroid vasculature in the shrinkage of fibroids is dependent upon subjects being hypoestrogenic.

Condition or disease Intervention/treatment Phase
Fibroid Leiomyoma Drug: GnRH analogue (Zoladex) Drug: GnRH antagonist-Cetrorelix Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.
Study Start Date : December 2008
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
GnRH analogue-Zoladex
Drug: GnRH analogue (Zoladex)
3.6mg subcutaneous implant. Monthly doses x 3.

Active Comparator: 2
GnRH antagonist plus GnRH analogue
Drug: GnRH analogue (Zoladex)
3.6mg subcutaneous implant. Monthly doses x 3.

Drug: GnRH antagonist-Cetrorelix
Subcutaneous injection 3mg x3 over 7 days
Other Name: Cetrotide

No Intervention: 3

Primary Outcome Measures :
  1. Uterine and fibroid volume [ Time Frame: 2010 ]

Secondary Outcome Measures :
  1. Uterine vascular perfusion, vasculature and extracellular matrix (ECM)content of fibroids. [ Time Frame: 2010 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age>18 years
  • Scheduled for hysterectomy with a fibroid uterus
  • At least one intramural non-pedunculated, submucosal or subserous fibroid(>2cm) or multiple small fibroids (uterine volume>200cm3)
  • Ability to understand and willingness to sign consent form
  • Normal smear within 3 years

Exclusion criteria:

  • Pregnant or lactating
  • Contra indication to MRI
  • Unable to tolerate supine position
  • Diabetes and/or renal or hepatic impairment
  • Contra indication to any of the study medications including gadolinium, MRI contrast

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746031

Layout table for location information
United Kingdom
University of Edinburgh/ Royal Infirmary of Edinburgh
Edinburgh, United Kingdom, EH16 4SA
Sponsors and Collaborators
University of Edinburgh
NHS Lothian
Layout table for investigator information
Principal Investigator: HILARY OD CRITCHLEY, MBChB;MD;FRCOG University of Edinburgh
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Other Study ID Numbers: REC number 08/MRE00/30
First Posted: September 3, 2008    Key Record Dates
Last Update Posted: October 25, 2010
Last Verified: October 2010
Keywords provided by University of Edinburgh:
MR imaging
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Prolactin Release-Inhibiting Factors
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Hormone Antagonists